Corrigendum to "Considerations and quality controls when analyzing cell-free tumor DNA" [Biomol. Detect. Quantif. 17 (2019) 100078]

Biomol Detect Quantif. 2019 Jun 18:17:100091. doi: 10.1016/j.bdq.2019.100091. eCollection 2019 Mar.

Gustav Johansson^{1

2

3}, Daniel Andersson¹, Stefan Filges¹, Junrui Li¹, Andreas Muth⁴, Tony E Godfrey⁵, Anders Ståhlberg^{1

2

6}

¹ Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90 Gothenburg, Sweden.
² Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
³ Respiratory Inflammation and Autoimmunity, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
⁴ Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Surgery, Boston University School of Medicine, 700 Albany Street, Boston, MA, 02118, USA.
⁶ Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.

Abstract

[This corrects the article DOI: 10.1016/j.bdq.2018.12.003.].